News
Trump reaches drug pricing deal with AstraZeneca
U.S. President Donald Trump participates in a bilateral meeting with Finland’s President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025.
Nathan Howard | Reuters
The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the U.S., MSNBC reported Friday.
The deal with AstraZeneca would follow a similar pact with U.S. drugmaker Pfizer, which was announced late last month.
President Donald Trump and AstraZeneca CEO Pascal Soriot will announce the agreement during a White House event on Friday, MSNBC reported, citing a White House official. AstraZeneca will agree to sell drugs directly to Medicaid patients at the lowest price offered in other developed countries, or what Trump calls “most-favored nation” pricing, on a coming government website called TrumpRx.gov, according to MSNBC.
Pfizer agreed to similar terms with the Trump administration and received a three-year exemption from pharmaceutical sector tariffs as part of the agreement, on the condition that it continued to invest in U.S. manufacturing.
It is unclear if the deal with AstraZeneca would also include such a carveout.
AstraZeneca in July said it would invest $50 billion in the U.S. by 2030. The company announced further details about those plans Friday ahead of the reported pricing deal announcement.
Trump has pushed drugmakers to cut prices and build out manufacturing in the U.S., as sky-high costs for medicines relative to other developed countries irk voters across the political spectrum. As his administration threatened pharmaceutical companies with tariffs as high as 250% in recent months, many drugmakers announced significant investments in the U.S.
Trump has said he aims to strike pricing deals with other major drugmakers in the weeks ahead.
“If we don’t make a deal, we’re going to tariff them,” he said late last month as he announced the Pfizer agreement.
This story is developing. Please check back for updates.
